Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
München
2024
|
| Schlagworte: | |
| Online-Zugang: | Volltext Volltext |
| Beschreibung: | 31 Blätter |
| DOI: | 10.5282/edoc.33949 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV049821080 | ||
| 003 | DE-604 | ||
| 007 | t | ||
| 008 | 240814s2024 gw m||| 00||| eng d | ||
| 015 | |a 24,O09 |2 dnb | ||
| 035 | |a (OCoLC)1454743875 | ||
| 035 | |a (DE-599)BVBBV049821080 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-384 |a DE-473 |a DE-703 |a DE-1051 |a DE-824 |a DE-29 |a DE-12 |a DE-91 |a DE-19 |a DE-1049 |a DE-92 |a DE-739 |a DE-898 |a DE-355 |a DE-706 |a DE-20 |a DE-1102 |a DE-860 |a DE-2174 | ||
| 084 | |8 1\p |a 616.994 |2 23ksdnb | ||
| 084 | |8 2\p |a 610 |2 23sdnb | ||
| 100 | 1 | |a Schulz, Thomas Ulrich |e Verfasser |0 (DE-588)1338316605 |4 aut | |
| 245 | 1 | 0 | |a Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life |c Thomas Ulrich Schulz |
| 264 | 1 | |a München |c 2024 | |
| 300 | |a 31 Blätter | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c München, Ludwig-Maximilians-Universität |d 2024 | ||
| 583 | 1 | |a Archivierung/Langzeitarchivierung gewährleistet |5 DE-101 |2 pdager | |
| 650 | 0 | 7 | |8 3\p |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |
| 650 | 0 | 7 | |8 4\p |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |
| 650 | 0 | 7 | |8 5\p |a Therapie |0 (DE-588)4059798-2 |2 gnd |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 776 | 1 | 8 | |i Erscheint auch als |n Online-Ausgabe |o urn:nbn:de:bvb:19-339496 |o 10.5282/edoc.33949 |
| 856 | 4 | 1 | |u https://doi.org/10.5282/edoc.33949 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 1 | |u https://nbn-resolving.org/urn:nbn:de:bvb:19-339496 |x Resolving-System |z kostenfrei |3 Volltext |
| 883 | 0 | |8 1\p |a emakn |c 1,00000 |d 20240813 |q DE-101 |u https://d-nb.info/provenance/plan#emakn | |
| 883 | 0 | |8 2\p |a emasg |c 0,91533 |d 20240813 |q DE-101 |u https://d-nb.info/provenance/plan#emasg | |
| 883 | 0 | |8 3\p |a emagnd |c 0,29148 |d 20240813 |q DE-101 |u https://d-nb.info/provenance/plan#emagnd | |
| 883 | 0 | |8 4\p |a emagnd |c 0,12458 |d 20240813 |q DE-101 |u https://d-nb.info/provenance/plan#emagnd | |
| 883 | 0 | |8 5\p |a emagnd |c 0,06121 |d 20240813 |q DE-101 |u https://d-nb.info/provenance/plan#emagnd | |
| 912 | |a ebook | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-035161273 | |
Datensatz im Suchindex
| _version_ | 1809767688379039744 |
|---|---|
| adam_text | |
| any_adam_object | |
| author | Schulz, Thomas Ulrich |
| author_GND | (DE-588)1338316605 |
| author_facet | Schulz, Thomas Ulrich |
| author_role | aut |
| author_sort | Schulz, Thomas Ulrich |
| author_variant | t u s tu tus |
| building | Verbundindex |
| bvnumber | BV049821080 |
| collection | ebook |
| ctrlnum | (OCoLC)1454743875 (DE-599)BVBBV049821080 |
| doi_str_mv | 10.5282/edoc.33949 |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV049821080</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">240814s2024 gw m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">24,O09</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1454743875</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049821080</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-2174</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">616.994</subfield><subfield code="2">23ksdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">2\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schulz, Thomas Ulrich</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1338316605</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life</subfield><subfield code="c">Thomas Ulrich Schulz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München</subfield><subfield code="c">2024</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">31 Blätter</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">München, Ludwig-Maximilians-Universität</subfield><subfield code="d">2024</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">Archivierung/Langzeitarchivierung gewährleistet</subfield><subfield code="5">DE-101</subfield><subfield code="2">pdager</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">3\p</subfield><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">4\p</subfield><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">5\p</subfield><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="776" ind1="1" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="o">urn:nbn:de:bvb:19-339496</subfield><subfield code="o">10.5282/edoc.33949</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.5282/edoc.33949</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:19-339496</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">emakn</subfield><subfield code="c">1,00000</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emakn</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">emasg</subfield><subfield code="c">0,91533</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emasg</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,29148</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">4\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,12458</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">5\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,06121</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-035161273</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV049821080 |
| illustrated | Not Illustrated |
| indexdate | 2024-09-10T00:42:43Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-035161273 |
| oclc_num | 1454743875 |
| open_access_boolean | 1 |
| owner | DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 DE-860 DE-2174 |
| owner_facet | DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 DE-860 DE-2174 |
| physical | 31 Blätter |
| psigel | ebook |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| record_format | marc |
| spelling | Schulz, Thomas Ulrich Verfasser (DE-588)1338316605 aut Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz München 2024 31 Blätter txt rdacontent n rdamedia nc rdacarrier Dissertation München, Ludwig-Maximilians-Universität 2024 Archivierung/Langzeitarchivierung gewährleistet DE-101 pdager 3\p Krebs Medizin (DE-588)4073781-0 gnd 4\p Immuntherapie (DE-588)4026640-0 gnd 5\p Therapie (DE-588)4059798-2 gnd (DE-588)4113937-9 Hochschulschrift gnd-content Erscheint auch als Online-Ausgabe urn:nbn:de:bvb:19-339496 10.5282/edoc.33949 https://doi.org/10.5282/edoc.33949 Verlag kostenfrei Volltext https://nbn-resolving.org/urn:nbn:de:bvb:19-339496 Resolving-System kostenfrei Volltext 1\p emakn 1,00000 20240813 DE-101 https://d-nb.info/provenance/plan#emakn 2\p emasg 0,91533 20240813 DE-101 https://d-nb.info/provenance/plan#emasg 3\p emagnd 0,29148 20240813 DE-101 https://d-nb.info/provenance/plan#emagnd 4\p emagnd 0,12458 20240813 DE-101 https://d-nb.info/provenance/plan#emagnd 5\p emagnd 0,06121 20240813 DE-101 https://d-nb.info/provenance/plan#emagnd |
| spellingShingle | Schulz, Thomas Ulrich Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life 3\p Krebs Medizin (DE-588)4073781-0 gnd 4\p Immuntherapie (DE-588)4026640-0 gnd 5\p Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4026640-0 (DE-588)4059798-2 (DE-588)4113937-9 |
| title | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life |
| title_auth | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life |
| title_exact_search | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life |
| title_full | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz |
| title_fullStr | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz |
| title_full_unstemmed | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz |
| title_short | Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life |
| title_sort | persistent immune related adverse events after cessation of checkpoint inhibitor therapy prevalence and impact on patients health related quality of life |
| topic | 3\p Krebs Medizin (DE-588)4073781-0 gnd 4\p Immuntherapie (DE-588)4026640-0 gnd 5\p Therapie (DE-588)4059798-2 gnd |
| topic_facet | Krebs Medizin Immuntherapie Therapie Hochschulschrift |
| url | https://doi.org/10.5282/edoc.33949 https://nbn-resolving.org/urn:nbn:de:bvb:19-339496 |
| work_keys_str_mv | AT schulzthomasulrich persistentimmunerelatedadverseeventsaftercessationofcheckpointinhibitortherapyprevalenceandimpactonpatientshealthrelatedqualityoflife |